Criteria to qualify for study: Drug used in study:
  • Completed EOS visit in Study NEOD001-201/ANC >1.0/Plt >75/Hgb>9.

AMY 04 NEOD001-OLE251

A phase 2b Open-label Extension Study to evaluate the Long-Term safety and efficacy of NEOD001 in subjects with light-chain (AL) Amyloidosis who were previously enrolled in Study neod001-201 (PRONTO)


Untreated

Criteria to qualify for study: Drug used in study:
  • Untreated
  • Serum M protein must be at least 0.5 g/dL
  • Urine M proteint must be at least 200 mg/24hr
  • A difference between the involved IG free light chain and uninvolved light chain of at least 5 mg/dL AND abnormal serum IG kappa lambda free light chain ratio
  • ANC must be at least 1000
  • PLT must be at least 75

CBCI-248 Karmanos 2011-155

Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease

ON HOLD